SHL Telemedicine Ltd (SHL) (NASDAQ: SHLT) (SIX: SHLTN), a provider and developer of advanced personal telemedicine solutions, on Monday announced the soft launch of the SmartHeart membership program in the US, marking a significant step forward in at-home healthcare.
This program is part of SHL's Direct-to-Consumer (D2C) initiative, offering a comprehensive subscription service that delivers at home professional cardiac care directly to the consumer.
The SmartHeart membership program is designed to revolutionise home-based access to cardiac care. It includes the innovative, user-friendly SmartHeart portable 12-lead ECG device, offering round-the-clock interpretation by board-certified cardiologists and on-demand telehealth visits. This initiative not only simplifies the process of conducting a full 12-lead ECG at home but also ensures convenient and dependable heart health management, meeting the evolving needs of today's healthcare consumers.
Subscribing members to SmartHeart are offered: a portable 12-lead ECG device,the SmartHeart ECG that allows high-quality 12-lead ECG performance anytime, anywhere; 24/7 cardiologist interpretation whereby subscribers receive expert ECG analysis from board-certified cardiologists; on-demand telehealth visits with onvenient access to medical professionals for timely consultations; and flexible subscription plans with tailored private-pay options ensure affordable access to advanced cardiac care.
SHL Telemedicine focuses on developing and marketing personal telemedicine systems, offering medical call centre services with a cardiovascular focus. The company provides services and devices to subscribers using telephonic and internet communication technology.
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study
Nicox and Glaukos sign exclusive research and licensing option agreement
Creo Medical forms strategic partnership with Micro-Tech via EUR36.7m subsidiary sale
Epitomee Medical's Capsule cleared by FDA for weight management
Eurofins strengthens biopharma testing in US with Infinity Labs acquisition